On Jun 29, 2021 SAGA Diagnostics closed a Series A round and raised SEK106,000,000 (€10.5 million) from Hadean Ventures, Sciety, Segulah Medical Acceleration, featuring lead by Segulah Medical Acceleration and the Sciety investment syndicate.

About the company: SAGA Diagnostics is located in Sweden, Europe. “SAGA is commercializing proprietary technologies to quantify cancer-associated genetic aberrations in tissue and liquid biopsy samples, and are uniquely capable of achieving limits of detection down to 0.001% mutant allele fraction. SAGA’s platform technologies, which are based on digital PCR and next-generation sequencing, are tools to be used in cancer patient stratification, therapy response monitoring, disease relapse identification, as well as in aiding in treatment decisions and as companion diagnostics.”

Company website: sagadiagnostics.com/